The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience

被引：0

作者：

Alasbali, Reem ^{[1
]}

Nasiri, Abdulrahman ^{[1
]}

Adam, Alfadil ^{[1
]}

Alhayli, Saud ^{[1
]}

Chaudhri, Naeem A. ^{[1
]}

Alshaibani, Alfadel ^{[1
]}

Albabtain, Abdulwahab ^{[1
]}

Samarkandi, Hadeel ^{[2
]}

Saad, Ayman ^{[1
]}

Alamer, Abdullah ^{[1
]}

Elhassan, Tusneem Ahmed M. ^{[2
]}

Alzahrani, Hazza A. ^{[1
]}

Ahmed, Syed Osman ^{[1
]}

Rasheed, Walid ^{[1
]}

Elfakih, Riad ^{[1
]}

Aljurf, Mahmoud ^{[1
]}

Ali, D. Alahmari ^{[1
]}

机构：

[1] KFSHRC, Dept Hematol, Stem Cell Transplantat & Cellular Therapy, Riyadh, Saudi Arabia

[2] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia

来源：

BLOOD | 2023年 / 142卷

关键词：

NHL; FL; CAR-T; CRS; ICANS;

D O I：

10.1182/blood-2023-182580

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 47 条

[11] Estimating costs of adverse events (AEs) and healthcare resource use (HRU) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) receiving tisagenlecleucel (tisa-cel) and axicabtagene ciloleucel (axi-cel): A summary of real-world evidence.
Yang, Hongbo
Qi, Cynthia Zhengyun
Dalal, Anand
Bollu, Vamsi
Zhang, Jie
Zhang, Su
Lim, Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[12] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Maloney, David G.
Kuruvilla, John
Fox, Christopher P.
Cartron, Guillaume
Li, Daniel
Hasskarl, Jens
Bonner, Ashley
Zhang, Yixie
Liu, Fei Fei
BLOOD, 2020, 136
[13] Real-Life CAR-T Cell Treatment in Large B-Cell Lymphomas Indicates That Axi-Cel and Tisa-Cel Have Similar Outcomes, but Long-Term Cytopenia Is an Emerging Problem
Chiappella, Annalisa
Guidetti, Anna
Dodero, Anna
Bramanti, Stefania
Zinzani, Pier Luigi
Santoro, Armando
Casadei, Beatrice
Di Rocco, Alice
Carrabba, Matteo Giovanni
Chiusolo, Patrizia
Martino, Massimo
Barbui, Anna Maria
Tisi, Maria Chiara
Saccardi, Riccardo
Perriello, Vincenzo Maria
Orciuolo, Enrico
Botto, Barbara
Russo, Domenico
Miceli, Rosalba
Ljevar, Silva
Carniti, Cristiana
Corradini, Paolo
BLOOD, 2021, 138 : 3867 - +
[14] Non-Western Real-World Experience of Axi-Cel CAR-T in Refractory/Relapsed B-Cell Lymphoma from a Tertiary Center in Saudi Arabia
Alsuhaibani, Khalid
Hejab, Amal
Ahmed, Syed Osman
Alahmari, Ali
Hanbali, Amr
Rasheed, Walid
Alshaibani, Alfadel
Chaudhri, Naeem A.
Saad, Ayman
Alotaibi, Shaykhah
Alkhaldi, Hanan
Alamer, Abdullah
Alfayez, Mansour
Alhayli, Saud
Shaheen, Marwan
Alfraih, Feras Abdulaziz
Alotaibi, Ahmad S.
Samarkandi, Hadeel
Syed, Farhatullah
Alsharif, Fahad
Almohareb, Fahad
Alzahrani, Hazza
Aljurf, Mahmoud
Elfakih, Riad
Albabtain, Abdulwahab
BLOOD, 2024, 144 : 7825 - 7825
[15] Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience
Ghafouri, Sanaz
Fenerty, Kathleen
Schiller, Gary
de Vos, Sven
Eradat, Herbert
Timmerman, John
Larson, Sarah
Mead, Monica
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : 861 - 872
[16] A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry
Bachy, Emmanuel
Le Gouill, Steven
Di Blasi, Roberta
Sesques, Pierre
Cartron, Guillaume
Beauvais, David
Roulin, Louise
Gros, Francois Xavier
Sylvain, Choquet
Bories, Pierre
Rubio, Marie Therese
Casasnovas, Rene-Olivier
Bay, Jacques-Olivier
Mohty, Mohamad
Joris, Magalie
Gastinne, Thomas
Tudesq, Jean Jacques
Chaillol, Isabelle
Broussais, Florence
Thieblemont, Catherine
Houot, Roch
Morschhauser, Franck
BLOOD, 2021, 138
[17] Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Lee, Dasom
Kambhampati, Swetha
Bobillo, Maria Silvina Odstrcil
Adedokun, Babatunde
Shadman, Mazyar
Olson, Amanda L.
Herrera, Alex F.
Lee, Catherine J.
Jacobson, Caron A.
Bye, Matthew
Hamadani, Mehdi
Kim, Soyoung
Dahiya, Saurabh
Hu, Zhen-Huan
Speth, Kelly
To, Christina
Mirjah, Debbie L.
Best, Timothy
Locke, Frederick L.
Ahmed, Nausheen
Tees, Michael T.
Pasquini, Marcelo C.
Ahmed, Sairah
BLOOD, 2024, 144 : 527 - 528
[18] Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
Cook, Michael Roderick
Shouval, Roni
Perales, Miguel-Angel
Bezerra, Evandro
Niu, Alex
Dahiya, Saurabh
Nastoupil, Loretta J.
Jacobson, Caron A.
Budde, L. Elizabeth
Olson, Amanda L.
Logan, Brent R.
Hu, Zhen-Huan
Wang, Hai-Lin
Luo, Zhong-Cheng
Kim, Jenny J.
Smith, Harry W.
Lee, Andrew
Sun, Fang
Pasquini, Marcelo
Locke, Frederick L.
BLOOD, 2023, 142
[19] Single-Center Experience of Axicabtagene Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Melody, Megan
Rahman, Zaid Abdel
Ernesto, Ayala
Gannon, Nicole
Roy, Vivek
Sher, Taimur
Ailawadhi, Sikander
Foran, James
Dabaja, Mohamed Kharfan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S267 - S268
[20] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
Khurana, Arushi
Bailey, Megumi
Iqbal, Madiha
Bansal, Radhika
Lee, Catherine J.
Hunter, Bradley
Lunning, Matthew A.
Jaglowski, Samantha
Jain, Michael D.
Dahiya, Saurabh
Bachanova, Veronika
Farooq, Umar
Ahmed, Sairah
Hill, Brian T.
Munoz, Javier L.
Patel, Krish
Oluwole, Olalekan O.
Lin, Yi
BLOOD, 2022, 140 : 4657 - 4660

← 1 2 3 4 5 →